<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza A virus (IAV) infection affects about 20% of the worldwide population annually [
 <xref rid="B1-viruses-10-00454" ref-type="bibr">1</xref>]. The 2009 influenza pandemic showed that the next pandemic could cause major adverse health and economic outcomes [
 <xref rid="B2-viruses-10-00454" ref-type="bibr">2</xref>]. While vaccines remain the primary means to prevent outbreaks, the effects of influenza vaccines are mild and regularly outpaced by the antigenic drift of the virus [
 <xref rid="B3-viruses-10-00454" ref-type="bibr">3</xref>]. As a result, stockpiling antiviral drugs in anticipation of a pandemic has been recommended, among other public health routines [
 <xref rid="B4-viruses-10-00454" ref-type="bibr">4</xref>]. The benefits of this approach, however, have been debated in terms of treating and preventing epidemic spread [
 <xref rid="B5-viruses-10-00454" ref-type="bibr">5</xref>,
 <xref rid="B6-viruses-10-00454" ref-type="bibr">6</xref>].
</p>
